机构公开数据差异较大,部分机构称临床妊娠率约90%、囊胚培养率约84%,行业普遍引用的活产率约60%—70%(多与 PGT 相关)。临床妊娠率不等于活产率,比较机构时应要求说明分母定义与统计周期。风险则分布在医疗、法律与机构三个层面,其中跨境法律风险最难由机构承担。
关键数据

成功率是营销最集中的地方,也是最容易被误读的地方。同一个90%,可能指临床妊娠、可能指囊胚形成、也可能只统计了特定年龄段。本篇不比较谁的数字更好看,而是解释数字怎么来的,以及哪些风险是机构无法替你承担的。
先分清三个成功率指标
先分清三个指标:获卵与囊胚形成率、临床妊娠率、活产率。它们的分母依次缩小,数字也依次下降。把临床妊娠率当作活产率来比较,是最常见的误判。
影响活产的五个变量
影响活产的核心变量有五个:卵子质量(与年龄强相关)、精子质量、胚胎质量与是否做 PGT、子宫内膜容受性与移植方案、孕母的健康状况。这五项里,前两项在委托方,中间两项在实验室,后两项在孕母与医疗团队。
风险要分层看
风险要分层看。医疗风险由合规机构与规范流程来降低;机构风险靠资质核验、分期付款与合同条款来控制;法律风险则基本无法转移——中国法律禁止代孕,境外合同在国内可能被认定无效,这一条只能由家庭提前评估并自行承担。
合规提示
本文为公开资料整理,不构成法律意见或医疗建议。政策、费用与流程可能变动,具体条款请以当地官方文本、医疗机构书面说明与签署合同为准。

Success rates are where marketing is densest and misreading is easiest. The same 90% may refer to clinical pregnancy, to blastocyst formation, or to a narrow age band. Rather than ranking headline figures, this guide explains how they are produced and which risks no provider can absorb for you.
Three different success metrics
Separate three metrics first: egg and blastocyst yield, clinical pregnancy, and live birth. Their denominators shrink in that order, and so do the numbers. Treating a clinical pregnancy rate as a live-birth rate is the most common error in comparison.
Five variables behind live birth
Five variables drive live birth: egg quality (strongly age-related), semen quality, embryo quality and whether PGT is used, endometrial receptivity and transfer protocol, and the surrogate's health. The first two belong to the intended parents, the middle two to the laboratory, the last two to the surrogate and clinical team.
Reading risk in layers
Risk should be read in layers. Medical risk is reduced by a licensed clinic and disciplined process; provider risk by credential checks, staged payment and contract terms; legal risk can barely be transferred at all. Chinese law prohibits surrogacy and an overseas contract may be held invalid in China, which only the family can assess in advance.
Important note
This article summarises publicly available information and is not legal or medical advice. Policies, prices and procedures change; rely on official local texts, written clinic information and your signed contract.
常见问题
吉尔吉斯斯坦代孕成功率有多高?+
代孕有哪些医疗风险?+
跨境代孕有哪些法律风险?+
中介跑路或机构倒闭怎么办?+
政策突然收紧该如何应对?+
哪些因素最影响吉尔吉斯斯坦代孕的成功率?+
为什么不同机构公布的成功率差异这么大?+
反复移植失败后,下一步通常怎么排查?+
代孕过程中出现医疗纠纷,应该如何处理?+
去吉尔吉斯斯坦做代孕需要买医疗保险吗?+
Frequently asked questions
What is the success rate of surrogacy in Kyrgyzstan?+
What medical risks does surrogacy involve?+
What legal risks arise in cross-border surrogacy?+
What if an agency disappears or a clinic closes?+
How should families prepare for a sudden policy tightening?+
Which factors most affect success?+
Why do clinics report such different success rates?+
What is investigated after repeated implantation failure?+
How should a medical dispute be handled?+
Is medical insurance needed for treatment in Kyrgyzstan?+
相关阅读
吉尔吉斯斯坦第三方助孕合法吗?法律框架、适用人群与政策变化
结论:合法。核心依据是《公民健康保护法》第57条,2024年1月12日第14号法律完成立法整合,2024年10月14日第616号内阁决议细化了代孕程序与合同范本。现行法律未禁止外国人,但要求其在吉境内合法居留。2025年已有限制外国人使用的法案进入公众讨论,尚未生效,政策存在不确定性。
适用人群与资格谁可以在吉尔吉斯斯坦做第三方助孕?单身、伴侣与高龄家庭的资格条件
吉尔吉斯斯坦法律不以婚姻状况或性取向设置限制,单身男女与已婚夫妇均可作为委托方;核心门槛不在身份,而在三件事:合法居留证件、医学诊断证明、以及在指定医疗机构完成的检查与评估。高龄或携带遗传病基因的家庭可以申请,但方案需个体化,PGT 等检测会明显影响时间与费用。
医疗流程与技术吉尔吉斯斯坦第三方助孕的医疗流程:从促排取卵到胚胎移植
典型流程为:前期咨询与医疗评估、证件准备与法律公证、促排卵与取卵、胚胎培养(可选 PGT)、匹配孕母与胚胎移植、孕期监测、分娩与出生登记、证件认证与回国。医疗侧的关键变量是卵巢储备、精子质量、胚胎质量与子宫内膜容受性,这四项决定了方案与周期长度。
费用与付款吉尔吉斯斯坦第三方助孕费用:总价构成、报价差异与付款节点
公开资料显示第三方辅助生殖全程约55万—100万元人民币,基础医疗周期约1.5万—3万美元。报价差异主要来自技术方案(是否含 PGT)、服务范围(是否含孕母补偿、法律与差旅)、移植次数承诺与机构资质。付款通常按签约定金、医疗启动、移植确认、分娩与证件办理分阶段进行。
扫码添加微信